Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Isatuximab (Primary) ; Diphenhydramine; Methylprednisolone; Ranitidine
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 Feb 2017 Planned number of patients changed from 63 to 61.
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.
- 12 Nov 2016 New trial record